Mok, Chi Chiu <br/><br/>
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.  [electronic resource] 

 -  Annals of the rheumatic diseases  May 2011 
 - 778-84 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/ard.2010.143453  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Biomarkers--metabolism<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--adverse effects<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Glucocorticoids--administration & dosage<br/>Hip Joint--physiopathology<br/>Humans<br/>Lipids--blood<br/>Lumbar Vertebrae--physiopathology<br/>Middle Aged<br/>Osteoporosis, Postmenopausal--chemically induced<br/>Prednisone--administration & dosage<br/>Raloxifene Hydrochloride--adverse effects<br/>Rheumatic Diseases--drug therapy